financetom
Business
financetom
/
Business
/
BRIEF-GD Culture Enters Into Share Exchange Agreement To Acquire Pallas Capital's Assets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-GD Culture Enters Into Share Exchange Agreement To Acquire Pallas Capital's Assets
Sep 16, 2025 6:23 AM

Sept 16 (Reuters) - GD Culture Group Ltd ( GDC ):

* GD CULTURE ENTERS INTO SHARE EXCHANGE AGREEMENT TO ACQUIRE

PALLAS CAPITAL'S ASSETS, INCLUDING 7,500 BITCOIN, FOR 39,189,344

SHARES

Source text:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Conavi Medical Q3 Net Loss Narrows; Updates on Novasight Launch
Conavi Medical Q3 Net Loss Narrows; Updates on Novasight Launch
Aug 29, 2025
07:41 AM EDT, 08/29/2025 (MT Newswires) -- Conavi Medical ( CNVIF ) on Friday said third-quarter net loss narrowed as it cut costs, while the company plans to launch its next-generation Novasight system in the U.S. next year. For Q3, net loss decreased to $3.6 million, or $0.05 per share, from a net loss of $13 million, or $2.12 per...
iRhythm Technologies Says Trial Showed Increased Atrial Fibrillation Detection With Zio Device
iRhythm Technologies Says Trial Showed Increased Atrial Fibrillation Detection With Zio Device
Aug 29, 2025
07:49 AM EDT, 08/29/2025 (MT Newswires) -- iRhythm Technologies ( IRTC ) said Friday that a clinical trial demonstrated that its Zio long-term continuous monitoring device led to increased atrial fibrillation detection and a shorter time to diagnosis. The trial was designed to determine whether the Zio device could improve atrial fibrillation detection in people aged 65 years and older...
NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell
NeoGenomics Says Court Decides to Invalidate Natera's Asserted Patents; Shares up Pre-Bell
Aug 29, 2025
07:49 AM EDT, 08/29/2025 (MT Newswires) -- NeoGenomics ( NEO ) said Friday that a North Carolina district court granted the company's motion for summary judgment that Natera's ( NTRA ) asserted patents are invalid for claiming ineligible subject matter. The move allows NeoGenomics ( NEO ) to continue to broadly commercialize its RaDaR ST molecular residual disease assay in...
Johnson & Johnson to Stop Clinical Development of Nipocalimab Combination Therapy for Rheumatoid Arthritis
Johnson & Johnson to Stop Clinical Development of Nipocalimab Combination Therapy for Rheumatoid Arthritis
Aug 29, 2025
07:43 AM EDT, 08/29/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that it will not proceed with the clinical development of nipocalimab in combination with an anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients with refractory disease. The company said the decision was based on the week 12 results of a phase 2a proof-of-concept study,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved